Share on LinkedInShare on LinkedIn

ARTICLE · 22 OCTOBER 2007

The Global IP Scorecard For Pharma & Biotech Compulsory Licenses

There's been a lot of buzz lately about various developing countries ordering Compulsory Licenses.

GlobalIntellectual Property

Please feel free to add to or comment on the scorecard at www.duncanbucknell.com/scorecards.

Countries, Products, Timing And Updates

There's been a lot of buzz lately about various developing countries ordering Compulsory Licenses. This scorecard tracks the countries, the products, timing of the ordered Licenses and provides updates as they arise.

Compulsory Licenses, (under Article 31 of TRIPS) have traditionally been ordered to enable access to medicines to people in developing countries who would otherwise not be able to afford them. The Licenses have typically been granted in respect of medicines to treat diseases such HIV/AIDS and other infectious diseases.

Part of the buzz which has recently arisen surrounds allegations that some countries have used the mechanism to drive down drug prices.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from